ASMB — ASSEMBLY BIOSCIENCES, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1426800 ·
Last close
$23.67
Market Cap
$481.94M
52W High
$39.71
52W Low
$21.80
ADV30
382,430
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 13,374,000 | — | -6,344,000 | -3,857,000 | 330,832,000 | 32,286,000 | 25,183,000 |
| Mar 2026 | 8,213,000 | — | -11,370,000 | -9,079,000 | 235,508,000 | 31,120,000 | 36,898,000 |
| Dec 2025 | 42,469,000 | — | 19,799,000 | 22,090,000 | 257,590,000 | 58,450,000 | 50,839,000 |
| Sep 2025 | 10,789,000 | — | -10,883,000 | -9,196,000 | 239,997,000 | 22,534,000 | 57,302,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-39,751,000
Investing CF
$-125,436,000
Financing CF
$172,894,000
CapEx
$-43,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.76
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-841,126,000
Inventory
—
Receivables
$451,000
ST Investments
$195,481,000
EBIT TTM
$-13,547,000
Pretax Income TTM
$-6,383,000
Interest Exp TTM
—
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$74,845,000
EBITDA
$-8,688,000
Free Cash Flow
$-27,865,750
Enterprise Value
$288,734,752
Total Cash
$320,360,992
Total Debt
$2,350,000
Shares Out
20,360,596
Trailing EPS
$1.24
Book Value
$15.40
ROE
-0.0%
ROA
-2.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 72,303,000 | -12,118,000 | -6,122,000 | 257,590,000 | 50,839,000 | 206,751,000 | -41,093,000 |
| Dec 2024 | 28,520,000 | -45,420,000 | -40,177,000 | 119,168,000 | 85,809,000 | 33,359,000 | -51,117,000 |
| Dec 2023 | 7,163,000 | -64,646,000 | -61,228,000 | 136,823,000 | 95,726,000 | 41,097,000 | 22,743,000 |
| Dec 2022 | 0 | -94,114,000 | -93,092,000 | 101,794,000 | 19,130,000 | 82,664,000 | -84,463,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.57
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $15.00 · spot: $23.65 · call volume: 99 · put volume: 14
Expected Move to 2026-12-18:
±$6.90
(29.18%) —
implied range
$16.75 –
$30.55
· ATM straddle on $22.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CAPR | CAPRICOR THERAPEUTICS, INC. | $486.04M | $8.36 | — |
| ARVN | ARVINAS, INC. | $489.72M | $7.59 | — |
| OVID | Ovid Therapeutics Inc. | $468.71M | $2.40 | — |
| KMDA | KAMADA LTD | $503.23M | $8.72 | — |
| PBYI | PUMA BIOTECHNOLOGY, INC. | $504.33M | $9.77 | — |
News headlines (Yahoo Finance, 1h cache)
Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference
2026-09-10 20:15 · Yahoo
Zacks.com featured highlights include EuroDry, RCM, Assembly Biosciences, Delcath and National Energy Services
2026-09-08 13:48 · Yahoo
Wall Street Analysts See a 35.71% Upside in Assembly Biosciences (ASMB): Can the Stock Really Move This High?
2026-09-07 13:55 · Yahoo
Should You Buy Assembly Biosciences (ASMB) After Golden Cross?
2026-09-04 13:55 · Yahoo
Are You Looking for a Top Momentum Pick? Why Assembly Biosciences (ASMB) is a Great Choice
2026-08-20 16:00 · Yahoo
Wall Street Analysts Think Assembly Biosciences (ASMB) Could Surge 40.66%: Read This Before Placing a Bet
2026-08-20 13:55 · Yahoo
Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates
2026-08-13 20:00 · Yahoo
Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead
2026-06-08 17:03 · Yahoo
Best Momentum Stocks to Buy for September 17th
2026-09-17 14:00 · Yahoo
Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program
2026-09-08 20:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.